- October 18, 2019
Biotech Says It Hurdled A Genetic Barrier, But Shares Gave Up A Breakout
Arrowhead Pharmaceuticals stock flirted with a breakout Friday after the biotech company said it’s experimenting with drugs that will “silence” multiple troublesome genes simultaneously. Previously, that was impossible, Chief Executive Christopher Anzalone said late Thursday on CNBC’s Mad Money. Arrowhead Pharmaceuticals (ARWR) is among a slew of biotech companies using technology called RNA interference to silence genes responsible for creating problematic proteins.
- October 18, 2019
Reata CEO on positive trial results for drug to treat Friedreich’s ataxia
Warren Huff, Reata Pharma CEO, joins CNBC’s “Power Lunch” team to discuss his company’s positive clinical trial results for a drug to treat the neuromuscular disease Friedreich’s ataxia.
- October 18, 2019
Lyme Disease Vaccine
If the fear of ticks prevents you from enjoying the great outdoors, there might be some good news on the horizon. Thomas Lingelbach with Valneva has been working on a new vaccine designed to ward off Lyme disease.
- October 18, 2019
Eye Drops To Reverse Vision Loss One Step Closer To Market
Eye drops that can reverse poor vision? It may sound like science fiction, but one Israeli company is aiming to bring this product to market. The drops passed their Phase 2b clinical trial earlier this month, meaning they’ve proven to improve farsightedness, the inability to see or read nearby objects, and are highly tolerable. Although results have yet to be released, Israel-based Orasis Pharmaceuticals, revealed details last week about the latest results of the Phase 2b study for their CSF-1 eye drops.
- October 17, 2019
Arrowhead CEO breaks down drug partnerships with Johnson & Johnson and Amgen
Jim Cramer chats with Arrowhead Pharmaceuticals CEO Christopher Anzalone about projects the company is working on to silence genes that cause rare genetic disorders.
- October 16, 2019
Pharma’s roller-coaster relationship with RNA therapies
Fortunes can shift precipitously in the drug-discovery world. At the start of the twenty-first century, all eyes were focused on a powerful gene-silencing technology called RNA interference (RNAi), and many companies saw the almost limitless potential of harnessing the tool to manipulate genes implicated in diseases.
- October 11, 2019
Kitov updates on US Consensi launch
Kitov Pharmaceuticals today announced its combination drug to treat osteoarthritis pain and hypertension.
- October 11, 2019
RedHill Biopharma contends with Crohn’s
RedHill Biopharma Ltd. announced today the full Week 52 results for all subjects in the Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (MAP US study) and supportive topline results from the open-label extension Phase 3 study (MAP US2 study).
